Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;15(3):190-5.
doi: 10.1111/j.1477-2574.2012.00528.x. Epub 2012 Jul 26.

Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection

Timucin Taner  1 , Thomas D Atwell, Lizhi Zhang, Trynda N Oberg, William S Harmsen, Seth W Slettedahl, Michael L Kendrick, David M Nagorney, Florencia G Que
Affiliations

Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection

Timucin Taner et al. HPB (Oxford). 2013 Mar.

Abstract

Background: Resection of liver metastases from neuroendocrine cancer (NEC) prolongs survival and provides durable symptom relief. Not all hepatic lesions are amenable to resection, particularly when there is multifocal involvement. In this study, it was hypothesized that ablation of concomitant non-resectable NEC liver metastases is safe and salvages patients who would not have been selected for cytoreductive surgery.

Methods: Patients who underwent adjuvant ablation of NEC liver metastases between 1995 and 2008 were reviewed. NEC was classified by patient and tumour characteristics. Regression and Kaplan-Meier models were used to compare variables and generate survival curves.

Results: Ninety-four patients underwent hepatic resection and intra-operative ablation of metastatic NEC. The median number of lesions ablated was 3, and median size was 1.4 cm. One abscess occurred at an ablation site. Local recurrence was detected in four patients (3.8%). Overall survival was 80% and 59% at 5 and 10 years. Age, gender, tumour type, grade, primary site and need for repeat ablation had no significant association with survival. The Ki67 proliferative index was a significant predictor of decreased survival. Symptom-free survival was 34% at 3 years and 16% at 5 years, independent of the tumour grade.

Conclusion: Concurrent ablation of NEC metastases to the liver not amenable to resection is safe and increases the candidacy of patients for cytoreductive surgery. Ablation performed intra-operatively and repeated post-operatively as needed provides significant symptom control regardless of the tumour grade.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall (a), and symptom-free survival (b) of patients after the combined resection and ablation. Actuarial survival estimates are shown under each graph
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432–445. et al. - PubMed
    1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer. 2003;97:934–959. - PubMed
    1. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol. 2002;13:614–621. et al. - PubMed
    1. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663. et al. - PubMed
    1. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129–3136. et al. - PubMed

MeSH terms